TOP - January 2022 Vol 15, No 1 – Online Only
Treatment with the investigational agent mosunetuzumab (RG7828) as monotherapy induced deep remissions in patients with relapsed/refractory follicular lymphoma, according to results of a recent trial presented at the ASH 2021 Annual Meeting and Exposition.
At the 11th Annual Summit of the Association for Value-Based Cancer Care in 2021, a panel of experts, moderated by Michael Reff, RPh, MBA, Founder and Executive Director, National Community Oncology Dispensing Association (NCODA), Cazenovia, NY, discussed the current and future state of Medically Integrated Pharmacy (MIP) and the benefits of this approach in oncology.
Adagrasib (MRTX849), an inhibitor of the KRASG12C mutation, showed promising activity as monotherapy and in combination with cetuximab (Erbitux) in patients with metastatic colorectal cancer (CRC) in the phase 1/2 KRYSTAL-1 trial.
The ongoing COVID-19 pandemic has brought to the forefront the importance of advance care planning.
In the January issue of The Oncology Pharmacist (TOP), we feature the latest news and updates relevant to pharmacy professionals working in the field of oncology.
Antibody–Drug Conjugate Shows Promising Activity in Patients with Advanced or Metastatic EGFR Mutation–Positive NSCLC
Patritumab deruxtecan (HER3-DxD), an investigational antibody–drug conjugate targeting the HER3 growth factor receptor, showed promising activity in patients with locally advanced or metastatic EGFR mutation–positive non–small-cell lung cancer (NSCLC) who had received previous EGFR tyrosine kinase inhibitor (TKI) therapy, according to interim results from a phase 1 dose-escalation and dose-expansion trial.
This section provides a brief overview of new cancer drugs and indications approved by the FDA between November 29, 2021, and December 15, 2021.
Oncologic drug pricing is being transformed with greater value in mind.
Experts Agree That Flexibility and Adaptability Are Essential for Future-Proofing Cancer Care Against Pandemics
Enhanced flexibility in delivery, increased investment in digital capability, and quick adaptation to events were some of the positive impacts of the COVID-19 pandemic on cancer care.
At the 11th Annual Summit of the Association for Value-Based Cancer Care (AVBCC) in 2021, health plans and employers discussed the utility of value-based contracting for managing oncology care costs while maintaining focus on outcomes of value for patients.
Page 1 of 2
Results 1 - 10 of 13
Results 1 - 10 of 13